SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):54P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Cheng, N.-M.
Right arrow Articles by Yen, T.-C.
PubMed
Right arrow Articles by Cheng, N.-M.
Right arrow Articles by Yen, T.-C.

Oncology-Clinical Diagnosis: Solid Tumors

Lung Cancer I

The impact of averaged CT on SUV in non-small cell lung cancer patients

Nai-Ming Cheng1, Kung-Chu Ho1, Chih-Teng Yu2, Yuan-Chang Liu3 and Tzu-Chen Yen1

1 Nuclear Medicine; 2 Chest Medicine; 3 Diagnostic Radiology, Chang Gung Memorial Hospital, Linkou, Taiwan

214

Objectives: Averaged CT (ACT) has been used to match the temporal resolution of PET and CT in cardiology studies. We tried to compare the results from ACT and helical CT (HCT) at PET/CT in non-small cell lung cancer (NSCLC). We systematically analyzed the changes of maximum standardized uptake value (SUVmax) at primary tumor and regional lymph nodes in NSCLC.

Methods: Totally 50 documented primary lung cancer patients (with 76 lung main tumors and 153 lymph nodes) were enrolled. All had both ACT and HCT at the same PET/CT scan. Both ACT and HCT were used for attenuation correction (AC) of the same PET emission data. Lesions determinations were based on histopathology or consensus at the lung cancer combined meeting. The SUVmax at main tumor and lymph nodes were measured by PET/CT (ACT) and PET/CT (HCT), separately. Paired-sample t-test was used for analysis. A 2-tailed P value < 0.05 is considered statistically significant.

Results: The SUVs measured in PET/ACT were significantly higher than those measured in PET/HCT in both main tumors and lymph nodes in early (p<0.0001, p<0.0001) and delayed (p<0.0001, p<0.0001) PET images. SUVmaxes of tumor with PET/ACT were significantly higher than with PET/HCT in upper (n=38, p<0.0001) and lower lung (n=27, p<0.0001). SUVmaxes at lymph nodes were significantly higher in PET/ACT than PET/HCT in superior mediastinal (n=56, p<0.0001), aortic (n=17, p=0.003), inferior mediastinal (n=27, p=0.001), and N1 nodes (n=53, p<0.0001).

Conclusions: Due to significantly higher SUVmax with PET/ACT than PET/HCT at both primary tumor and lymph nodes, PET/ACT has high potential in radiation treatment planning and monitoring the therapeutic response in NSCLC patients in the future.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Cheng, N.-M.
Right arrow Articles by Yen, T.-C.
PubMed
Right arrow Articles by Cheng, N.-M.
Right arrow Articles by Yen, T.-C.